=====================
Roadman Investments Corp. (RMANF)
Alert Price: $0.07
Investor Presentation
Website | Recent News
========================
Members,
As cannabis legalization spreads across the globe, another mind-altering drug is trying to follow in its tracks: Mushrooms.
Denver voted in May to decriminalize the fungus that contains psilocybin, a psychedelic compound popularized by ’60s counterculture. Oakland, Calif. followed Denver’s lead a few weeks later and Oregon is trying to get a similar measure on the ballot for 2020.
Advocates say mushrooms have untapped medical potential that could be as big as cannabis, particularly for treating depression and addiction. The U.S. Food and Drug Administration granted “breakthrough therapy” status in October to Compass Pathways Ltd. to test the drug for treatment-resistant depression, expediting the development process. The London-based company says it’s now proceeding with a large-scale clinical trial in Europe and North America.
With their strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”), our latest trade idea RMANF (Roadman Investments Corp.), has cemented themselves as a first mover in a Mushroom Market which is expected to reach USD 34.3 billion by 2024!
The Company was just listed on U.S. exchanges via the OTC, but has been trading on the Toronto and Frankfurt stock exchanges.
We are excited to be the first financial publication to provide coverage on this industry first mover, and we are urging all of our members to start their research on this IPO style alert immediately.
About Roadman Investments
Roadman Investments is a Canadian investment firm that strives to actively drive innovation and accelerate growth within its portfolio holdings, with the objective of realizing alpha returns. Roadman is mandated with deploying investment capital and advisory services to both public and private companies. RMANF is engaged in the business of incubating and working with start up entities in with a view to generate capital and generate returns for its shareholders via the tactical deployment of capital across the resource , agricultural, financial services, technology and health and wellness verticals.
RMANF Is Currently Focusing On the Following Sectors:
Agricultural
Financial Services
Technology
Health and Wellness
RMANF is listed on three seperate exchanges: OTC: RMANF |TSX: LITT | FWB:1QD
Investment Philosophy
RMANF's portfolio selection goes through methodical analysis and our company uses a broad spectrum of investment strategies across industries and capitalization ranges. They analyze not only the financial and business prospects of the companies they invest in but also the fundamental macro drivers of the industry.
Investment Criteria
Roadman will consider any deal structure if the opportunity is accretive for their portfolio companies. The company focuses on majority acquisitions and minority investments will be considered in special situations.
Revenue: $1-10 million
EBITDA: $500K- 5 million
Industries: Health and Wellness , Agriculture, Financial services and Technology
Business Model: Recurring revenue model and Licensing
Management: Retention of existing management and key players preferred, but not necessary
Location: Worldwide
Exposure to emerging industries primed for geometric growth
Strong potential for accretive revenue and profitability
Ability to generate alpha returns
Evidence of potential dominance in market segment and/or geographic location
RMANF Is Capitalizing $210B Alternative Health Sector
Structural shifts are transforming the health care industry and RMANF is focused on investing in disruptive alternative health companies that offer tremendous potential. RMANF is committed to investing in breakthrough products, devices, treatments and health supplements that promote holistic health and wellness .
Yesterday, the Company announced that is has completed a C$150,000.00 strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”).
Champignon is a private, research-driven company specializing in the formulation and end distribution of a suite of premium artisanal mushroom health supplements, with the objective of promoting holistic health and wellness . Champignon is equipped with proprietary formulations for three flagship mushroom-extract-infused tea blends and is in the process of conducting extensive taste and product quality tests.
The Company invites all current and prospective shareholders to visit the Champignon corporate website by following the below stated URL:
champignonbrands.com/
Luke Montaine, Chief Executive Officer and a Director of Roadman Investments stated: “Roadman’s tactical deployment of capital into the burgeoning craft mushroom vertical is indicative of popular opinion shifting within the space. On May 8th, 2019, Denver voters approved Initiative 301, a measure that prohibits the city’s government from deploying resources to impose criminal penalties relating to the consumption and possession of psilocybin by adults over 21 years of age. The passage of Initiative 301 comes amid a recent resurgence in the study of psilocybin and its potential medical applications. Researchers worldwide are increasingly examining whether psilocybin may alleviate symptoms associated with conditions such as anxiety, obsessive-compulsive disorder, major depressive disorder and alcohol dependence.
London-based start-up Compass Pathways has produced 20,000 individual doses of psilocybin for use in clinical trials across North America and Europe. Compass boasts an advisory board of esteemed scientists and has attracted high-profile financings from Peter Thiel, Christian Angermayer and Mike Novogratz, among others.
Leveraging its newly formed health and wellness committee, Roadman will continue to actively pursue alpha generating investments within this flourishing sector. The global mushroom market accounted for US$38.13 billion in 2017 and is forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. This growth will be further bolstered by the increasing demand for meat substitutes, as well as shifting consumer preference towards vegan foods .”
Champignon’s flagship e-commerce store includes a selection of craft mushroom-infused teas and ancillary accessories, earmarked for worldwide distribution. Champignon invites all current and prospective shareholders to visit its e-commerce store and review its Vitality Superteas branded product offering by following the below stated URL:
vitalitysuperteas.com
Kevin Matthews, Advisory Board member and Chair of Roadman Investments’ Health and Wellness Committee stated: “We continue to be encouraged by the recent growth within the bourgeoning health and wellness vertical and are actively looking to deploy additional capital into promising, high growth companies. As a result of recent landmark legislative shifts, Roadman’s dedicated Health and Wellness committee is currently evaluating complimentary investments within the medicinal mushroom sector, with the objective of augmenting Champignon’s mushroom-extract-infused tea formulations”.
www.prnewswire.com/news-releases......
THE MUSHROOM MARKET
According to market research firm Mordor Intelligence the Global Functional
Mushroom Market is expected to reach USD 34.3 billion by 2024 with a CAGR of
8.04%.
Much like cannabis before it, psychedelic compounds found in mushrooms have
often been maligned by mainstream society. A growing body of evidence shows that chemicals contained in certain mushrooms could be used to treat various mental health problems.
ALTERNATIVE TREATMENTS FOR DEPRESSION
The World Health Organization projects that there are over 300 million people worldwide dealing with depression.*
Research showing the immense benefits of mushroom medicine is growing.
The $15 billion-dollar global Anti-Depressant market can be disrupted by chemicals found in mushrooms as treatments go mainstream.*
REGULATORY CHANGE
In 2018 the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for psilocybin-assisted therapy for treatmentresistant depression.
The cities of Denver and Oakland California has voted to decriminalize the fungus that contains psilocybin, a psychedelic compound. The state of Oregon is pushing to get a similar measure on the ballot for 2020 and the wave of regulatory change is projected to continue.
Investment in Champignon Brands Inc.
Champignon Brands Inc. is a Canadian based company dedicated to promoting the
cultivation and proliferation of high quality medicinal mushrooms and health
supplements. Roadman’s executives have been assisting in the product development
and commercialization of a proprietary medicinal mushroom infused tea brand.
Initial agreement is signed that allows the company to:
Appoint a director
Inspect records and attend meetings
Right of first refusal in any future equity offerings at a price of $0.05 per share or higher
Market Outlook
The global complementary and alternative medicine market size is expected to generate a revenue of USD 210.81 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 17.07% during the forecast period. Factors such as the increasing adoption and usage of natural supplements/wellness medicine coupled with government initiatives to promote adoption of the therapy is expected to create revenue generation avenues.
Complementary and alternative forms of therapy are used in the treatment of chronic ailments, long-term pain among others and are also used for additional vitamins and other dietary supplementation of regular diet. Moreover, with considerable increase in the costs of conventional medicine and inclination towards body wellness rather than pharmaceutical cure is likely to boost the market over the forecast period.
Approximately two third population of most of the developed and developing countries has reported using one or the other form of alternative or complementary medicine. Certain countries are moving towards legalization of some alternative medicine and therapies backed with approved clinical data.
The global Mushroom market accounted for US$ 38.13 Bn in 2017, expanding at a CAGR of 7.9% from 2018 to 2026.
Rising consumption of processed food items, rising consumer awareness regarding the health benefits offered by mushrooms, and improvement in packaging technologies are some of the key factors influencing the growth of the mushroom market at present.
The Bottom Line
This is a rare chance to build a position in a company that is new to U.S. exchanges.
RMANF is a first-mover in a multi-billion dollar sector.
We love these IPO type opportunities, and we are very excited to see the type of growth RMANF is going to have.
As such, we are urging all members to act fast, start their research, and make sure to add RMANF to the top of their watchlist!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by Roadman Investments Corp. to conduct a one-day investor relations advertising and marketing campaign for RMANF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Roadman Investments Corp. (RMANF)
Alert Price: $0.07
Investor Presentation
Website | Recent News
========================
Members,
As cannabis legalization spreads across the globe, another mind-altering drug is trying to follow in its tracks: Mushrooms.
Denver voted in May to decriminalize the fungus that contains psilocybin, a psychedelic compound popularized by ’60s counterculture. Oakland, Calif. followed Denver’s lead a few weeks later and Oregon is trying to get a similar measure on the ballot for 2020.
Advocates say mushrooms have untapped medical potential that could be as big as cannabis, particularly for treating depression and addiction. The U.S. Food and Drug Administration granted “breakthrough therapy” status in October to Compass Pathways Ltd. to test the drug for treatment-resistant depression, expediting the development process. The London-based company says it’s now proceeding with a large-scale clinical trial in Europe and North America.
With their strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”), our latest trade idea RMANF (Roadman Investments Corp.), has cemented themselves as a first mover in a Mushroom Market which is expected to reach USD 34.3 billion by 2024!
The Company was just listed on U.S. exchanges via the OTC, but has been trading on the Toronto and Frankfurt stock exchanges.
We are excited to be the first financial publication to provide coverage on this industry first mover, and we are urging all of our members to start their research on this IPO style alert immediately.
About Roadman Investments
Roadman Investments is a Canadian investment firm that strives to actively drive innovation and accelerate growth within its portfolio holdings, with the objective of realizing alpha returns. Roadman is mandated with deploying investment capital and advisory services to both public and private companies. RMANF is engaged in the business of incubating and working with start up entities in with a view to generate capital and generate returns for its shareholders via the tactical deployment of capital across the resource , agricultural, financial services, technology and health and wellness verticals.
RMANF Is Currently Focusing On the Following Sectors:
Agricultural
Financial Services
Technology
Health and Wellness
RMANF is listed on three seperate exchanges: OTC: RMANF |TSX: LITT | FWB:1QD
Investment Philosophy
RMANF's portfolio selection goes through methodical analysis and our company uses a broad spectrum of investment strategies across industries and capitalization ranges. They analyze not only the financial and business prospects of the companies they invest in but also the fundamental macro drivers of the industry.
Investment Criteria
Roadman will consider any deal structure if the opportunity is accretive for their portfolio companies. The company focuses on majority acquisitions and minority investments will be considered in special situations.
Revenue: $1-10 million
EBITDA: $500K- 5 million
Industries: Health and Wellness , Agriculture, Financial services and Technology
Business Model: Recurring revenue model and Licensing
Management: Retention of existing management and key players preferred, but not necessary
Location: Worldwide
Exposure to emerging industries primed for geometric growth
Strong potential for accretive revenue and profitability
Ability to generate alpha returns
Evidence of potential dominance in market segment and/or geographic location
RMANF Is Capitalizing $210B Alternative Health Sector
Structural shifts are transforming the health care industry and RMANF is focused on investing in disruptive alternative health companies that offer tremendous potential. RMANF is committed to investing in breakthrough products, devices, treatments and health supplements that promote holistic health and wellness .
Yesterday, the Company announced that is has completed a C$150,000.00 strategic investment in British Columbia-based craft mushroom distributor and product formulator Champignon Brands Inc. (“Champignon”).
Champignon is a private, research-driven company specializing in the formulation and end distribution of a suite of premium artisanal mushroom health supplements, with the objective of promoting holistic health and wellness . Champignon is equipped with proprietary formulations for three flagship mushroom-extract-infused tea blends and is in the process of conducting extensive taste and product quality tests.
The Company invites all current and prospective shareholders to visit the Champignon corporate website by following the below stated URL:
champignonbrands.com/
Luke Montaine, Chief Executive Officer and a Director of Roadman Investments stated: “Roadman’s tactical deployment of capital into the burgeoning craft mushroom vertical is indicative of popular opinion shifting within the space. On May 8th, 2019, Denver voters approved Initiative 301, a measure that prohibits the city’s government from deploying resources to impose criminal penalties relating to the consumption and possession of psilocybin by adults over 21 years of age. The passage of Initiative 301 comes amid a recent resurgence in the study of psilocybin and its potential medical applications. Researchers worldwide are increasingly examining whether psilocybin may alleviate symptoms associated with conditions such as anxiety, obsessive-compulsive disorder, major depressive disorder and alcohol dependence.
London-based start-up Compass Pathways has produced 20,000 individual doses of psilocybin for use in clinical trials across North America and Europe. Compass boasts an advisory board of esteemed scientists and has attracted high-profile financings from Peter Thiel, Christian Angermayer and Mike Novogratz, among others.
Leveraging its newly formed health and wellness committee, Roadman will continue to actively pursue alpha generating investments within this flourishing sector. The global mushroom market accounted for US$38.13 billion in 2017 and is forecasted to expand at a CAGR of 7.9 per cent from 2018 to 2026. This growth will be further bolstered by the increasing demand for meat substitutes, as well as shifting consumer preference towards vegan foods .”
Champignon’s flagship e-commerce store includes a selection of craft mushroom-infused teas and ancillary accessories, earmarked for worldwide distribution. Champignon invites all current and prospective shareholders to visit its e-commerce store and review its Vitality Superteas branded product offering by following the below stated URL:
vitalitysuperteas.com
Kevin Matthews, Advisory Board member and Chair of Roadman Investments’ Health and Wellness Committee stated: “We continue to be encouraged by the recent growth within the bourgeoning health and wellness vertical and are actively looking to deploy additional capital into promising, high growth companies. As a result of recent landmark legislative shifts, Roadman’s dedicated Health and Wellness committee is currently evaluating complimentary investments within the medicinal mushroom sector, with the objective of augmenting Champignon’s mushroom-extract-infused tea formulations”.
www.prnewswire.com/news-releases......
THE MUSHROOM MARKET
According to market research firm Mordor Intelligence the Global Functional
Mushroom Market is expected to reach USD 34.3 billion by 2024 with a CAGR of
8.04%.
Much like cannabis before it, psychedelic compounds found in mushrooms have
often been maligned by mainstream society. A growing body of evidence shows that chemicals contained in certain mushrooms could be used to treat various mental health problems.
ALTERNATIVE TREATMENTS FOR DEPRESSION
The World Health Organization projects that there are over 300 million people worldwide dealing with depression.*
Research showing the immense benefits of mushroom medicine is growing.
The $15 billion-dollar global Anti-Depressant market can be disrupted by chemicals found in mushrooms as treatments go mainstream.*
REGULATORY CHANGE
In 2018 the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for psilocybin-assisted therapy for treatmentresistant depression.
The cities of Denver and Oakland California has voted to decriminalize the fungus that contains psilocybin, a psychedelic compound. The state of Oregon is pushing to get a similar measure on the ballot for 2020 and the wave of regulatory change is projected to continue.
Investment in Champignon Brands Inc.
Champignon Brands Inc. is a Canadian based company dedicated to promoting the
cultivation and proliferation of high quality medicinal mushrooms and health
supplements. Roadman’s executives have been assisting in the product development
and commercialization of a proprietary medicinal mushroom infused tea brand.
Initial agreement is signed that allows the company to:
Appoint a director
Inspect records and attend meetings
Right of first refusal in any future equity offerings at a price of $0.05 per share or higher
Market Outlook
The global complementary and alternative medicine market size is expected to generate a revenue of USD 210.81 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to expand at a CAGR of 17.07% during the forecast period. Factors such as the increasing adoption and usage of natural supplements/wellness medicine coupled with government initiatives to promote adoption of the therapy is expected to create revenue generation avenues.
Complementary and alternative forms of therapy are used in the treatment of chronic ailments, long-term pain among others and are also used for additional vitamins and other dietary supplementation of regular diet. Moreover, with considerable increase in the costs of conventional medicine and inclination towards body wellness rather than pharmaceutical cure is likely to boost the market over the forecast period.
Approximately two third population of most of the developed and developing countries has reported using one or the other form of alternative or complementary medicine. Certain countries are moving towards legalization of some alternative medicine and therapies backed with approved clinical data.
The global Mushroom market accounted for US$ 38.13 Bn in 2017, expanding at a CAGR of 7.9% from 2018 to 2026.
Rising consumption of processed food items, rising consumer awareness regarding the health benefits offered by mushrooms, and improvement in packaging technologies are some of the key factors influencing the growth of the mushroom market at present.
The Bottom Line
This is a rare chance to build a position in a company that is new to U.S. exchanges.
RMANF is a first-mover in a multi-billion dollar sector.
We love these IPO type opportunities, and we are very excited to see the type of growth RMANF is going to have.
As such, we are urging all members to act fast, start their research, and make sure to add RMANF to the top of their watchlist!
(*Remember to use a Stop-Loss Order or basic Limit Order to protect your gains, as well as limit possible losses.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStockLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned herewithin, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated fifteen thousand dollars by Roadman Investments Corp. to conduct a one-day investor relations advertising and marketing campaign for RMANF. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
⭐⭐⭐ Sign Up for Free ⭐⭐⭐
1) Download our App on Google Play! dexwirenews.com/APP
2) Text Message Notifications: dexwirenews.com/SMS
3) Telegram: t.me/DEXWireNews
4) Follow Us on our Social Networks
1) Download our App on Google Play! dexwirenews.com/APP
2) Text Message Notifications: dexwirenews.com/SMS
3) Telegram: t.me/DEXWireNews
4) Follow Us on our Social Networks